New drug shows promise for Hard-to-Treat cancers with p53 gene

NCT ID NCT02264613

Completed Disease control Sponsor: Aileron Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA PERIPHERAL T-CELL LYMPHOMA SOLID TUMOR

Contacts and locations

Locations

Study site

Birmingham, Alabama, 35294, United States
Study site

Duarte, California, 91010, United States
Study site

Denver, Colorado, 80218, United States
Study site

Sarasota, Florida, 34232, United States
Study site

Tampa, Florida, 33612, United States
Study site

Boston, Massachusetts, 02114, United States
Study site

Boston, Massachusetts, 02215, United States
Study site

New York, New York, 10065, United States
Study site

The Bronx, New York, 10461, United States
Study site

Greenville, South Carolina, 29605, United States
Study site

Nashville, Tennessee, 37203, United States
Study site

Houston, Texas, 77030, United States
Study site

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.